Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.
作者信息
Holsinger Floyd Christopher, Piha-Paul Sarina Anne, Janku Filip, Hong David S, Atkins Johnique T, Tsimberidou Apostolia M, Kurzrock Razelle
机构信息
University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
J Clin Oncol. 2013 Mar 20;31(9):e137-40. doi: 10.1200/JCO.2012.43.2716. Epub 2013 Jan 28.
Abstract
摘要
相似文献
1
Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.
J Clin Oncol. 2013 Mar 20;31(9):e137-40. doi: 10.1200/JCO.2012.43.2716. Epub 2013 Jan 28.
2
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
Mol Cancer Ther. 2014 Nov;13(11):2738-50. doi: 10.1158/1535-7163.MCT-13-1090. Epub 2014 Sep 5.
3
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25.
4
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Oncotarget. 2017 Mar 28;8(13):22203-22217. doi: 10.18632/oncotarget.14729.
5
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Ann Oncol. 2017 Oct 1;28(10):2533-2538. doi: 10.1093/annonc/mdx346.
6
Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Clin Cancer Res. 2012 Oct 1;18(19):5304-13. doi: 10.1158/1078-0432.CCR-12-1371. Epub 2012 Aug 2.
7
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Clin Cancer Res. 2015 Sep 1;21(17):3946-56. doi: 10.1158/1078-0432.CCR-14-3377. Epub 2015 May 14.
8
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Head Neck. 2016 Dec;38(12):1759-1764. doi: 10.1002/hed.24501. Epub 2016 May 27.
9
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Curr Opin Oncol. 2008 May;20(3):256-63. doi: 10.1097/CCO.0b013e3282f9b575.
10
Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.
Cancer Discov. 2013 Jul;3(7):722-5. doi: 10.1158/2159-8290.CD-13-0239.
引用本文的文献
1
The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma.
Cancers (Basel). 2019 Aug 14;11(8):1169. doi: 10.3390/cancers11081169.
2
Biomarker driven treatment of head and neck squamous cell cancer.
Cancers Head Neck. 2017 Aug 29;2:6. doi: 10.1186/s41199-017-0025-1. eCollection 2017.
3
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Nat Med. 2019 May;25(5):751-758. doi: 10.1038/s41591-019-0424-4. Epub 2019 Apr 22.
4
Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness.
Cancer Immunol Res. 2019 Jun;7(6):866-873. doi: 10.1158/2326-6066.CIR-18-0716. Epub 2019 Apr 19.
5
Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
Cancers (Basel). 2019 Apr 3;11(4):472. doi: 10.3390/cancers11040472.
6
PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.
Oral Oncol. 2019 Apr;91:69-78. doi: 10.1016/j.oraloncology.2019.02.026. Epub 2019 Mar 4.
7
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Ann Oncol. 2017 Oct 1;28(10):2533-2538. doi: 10.1093/annonc/mdx346.
8
Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.
Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.
9
Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.
Cell Cycle. 2015;14(14):2355-61. doi: 10.1080/15384101.2015.1053669. Epub 2015 Jun 1.
10
Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer.
Cell Cycle. 2015;14(11):1730-7. doi: 10.1080/15384101.2015.1033596.
本文引用的文献
1
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
J Clin Oncol. 2012 Mar 10;30(8):777-82. doi: 10.1200/JCO.2011.36.1196. Epub 2012 Jan 23.
2
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks.
Biochem J. 2012 Jan 1;441(1):1-21. doi: 10.1042/BJ20110892.
3
Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.
Head Neck. 2013 Mar;35(3):443-53. doi: 10.1002/hed.21910. Epub 2011 Nov 2.
4
Human papillomavirus and rising oropharyngeal cancer incidence in the United States.
J Clin Oncol. 2011 Nov 10;29(32):4294-301. doi: 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3.
5
Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.
J Clin Oncol. 2011 Sep 10;29(26):e727-30. doi: 10.1200/JCO.2011.36.2095. Epub 2011 Aug 15.
6
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7.
7
Human papillomavirus and survival of patients with oropharyngeal cancer.
N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.
8
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.
Cancer Cell. 2010 Mar 16;17(3):249-61. doi: 10.1016/j.ccr.2010.01.021.
9
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.
10
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.
Zotero 插件